Dual lineage inhibition of ETV1 and KIT disrupts the ETV1-KIT feed forward circuit and potentiates Imatinib antitumor effect in GIST |
Effect of secondary KIT mutations on growth of GIST cells in the absence of selective pressure by imatinib in isogenic models of imatinib resistance |
Second Line Treatment in Exon 11 Mutated Gist Patient: Imatinib Dose Escalation Or Sunitinib? Retrospective Analysis Of A Multi-Institutional Experience |
Dystrophin is a Tumor Supressor in Human Myogenic Cancers |
Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activating and drug-resistant KIT mutants found in GIST |
Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor (GIST) |
Correlation of PET/CT and CT RECIST Response in GIST Patients with PDGFRA D842V Gene Mutations Treated with Crenolanib |
An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST) |
An Overview of the GRID Study: |
Overview of Dose Modifications with STIVARGA® (regorafenib) |
Metabolomic profiling of Gastrointestinal Stromal Tumor (GIST) in Human Tissue Samples and Xenografts |
Analysis of serum protein biomarkers and circulating tumor DNA for activity of dovitinib in patients with |
Optimizing Management of Sunitinib Treatment in a Worldwide Treatment-use Trial of Patients with Advanced Gastrointestinal Stromal Tumor View Poster (.pdf) |
Continued Sunitinib Treatment after Progressive Disease in a Worldwide Treatment-use Trial |